Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.54 -3.2%	$2.55	$0.80 ▼ $4.08	$927.89M	0.85	3.18 million shs	5.10 million shs
CRDF Cardiff Oncology	$3.73 -1.7%	$2.99	$2.01 ▼ $5.64	$247.81M	1.61	1.17 million shs	600,295 shs
CVAC CureVac	$5.54 -1.2%	$3.70	$2.37 ▼ $5.72	$1.24B	2.49	976,500 shs	3.55 million shs
ELVN Enliven Therapeutics	$22.15 +12.6%	$18.18	$13.30 ▼ $30.03	$1.08B	0.79	313,742 shs	1.96 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+2.24%	-1.08%	+47.18%	+61.50%	+214.66%
CRDF Cardiff Oncology	-2.07%	+4.70%	+39.34%	-5.25%	+28.47%
CVAC CureVac	+37.59%	+25.56%	+65.19%	+86.05%	+34.94%
ELVN Enliven Therapeutics	+0.31%	-8.00%	-1.85%	-5.21%	-13.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.9758 of 5 stars	3.6	2.0	4.0	2.8	0.8	0.6
CRDF Cardiff Oncology	1.8487 of 5 stars	3.5	0.0	0.0	4.3	0.0	0.6
CVAC CureVac	4.3856 of 5 stars	3.5	4.0	4.8	2.5	0.0	1.3
ELVN Enliven Therapeutics	2.5509 of 5 stars	3.5	1.0	0.0	2.8	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	90.95% Upside
CRDF Cardiff Oncology	3.00	Buy	$12.00	222.15% Upside
CVAC CureVac	2.67	Moderate Buy	$9.00	62.60% Upside
ELVN Enliven Therapeutics	3.00	Buy	$37.25	68.21% Upside

Current Analyst Ratings Breakdown

Latest CRDF, AKBA, CVAC, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/28/2025	CVAC CureVac	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$10.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
4/30/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/1/2025	AKBA Akebia Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$184.91M	5.02	N/A	N/A	($0.16) per share	-22.09
CRDF Cardiff Oncology	$587K	422.16	N/A	N/A	$1.56 per share	2.39
CVAC CureVac	$523.70M	2.37	N/A	N/A	$2.50 per share	2.21
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$5.97 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$51.92M	-$0.21	N/A	N/A	N/A	-27.07%	N/A	-20.57%	8/6/2025 (Estimated)
CRDF Cardiff Oncology	-$41.44M	-$0.92	N/A	N/A	N/A	-6,238.17%	-73.97%	-60.40%	8/14/2025 (Estimated)
CVAC CureVac	-$281.58M	$0.92	10.06	N/A	N/A	20.72%	21.98%	15.72%	8/13/2025 (Estimated)
ELVN Enliven Therapeutics	-$71.58M	-$1.92	N/A	N/A	N/A	N/A	-29.46%	-27.33%	8/12/2025 (Estimated)

Latest CRDF, AKBA, CVAC, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
4/10/2025	Q4 2024	CVAC CureVac	-$0.14	-$0.15	-$0.01	-$0.15	$6.40 million	$15.44 million
3/13/2025	Q4 2024	AKBA Akebia Therapeutics	-$0.05	-$0.10	-$0.05	-$0.10	$37.36 million	$46.50 million
3/13/2025	Q4 2024	ELVN Enliven Therapeutics	-$0.53	-$0.46	+$0.07	-$0.46	N/A	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	N/A	1.52	1.21
CRDF Cardiff Oncology	N/A	4.74	4.74
CVAC CureVac	0.05	6.20	6.19
ELVN Enliven Therapeutics	N/A	17.44	17.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
CRDF Cardiff Oncology	16.29%
CVAC CureVac	17.26%
ELVN Enliven Therapeutics	95.08%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
CRDF Cardiff Oncology	7.70%
CVAC CureVac	2.15%
ELVN Enliven Therapeutics	25.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	209.24 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	47.15 million	Optionable
CVAC CureVac	880	224.34 million	219.07 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	34.59 million	Optionable

CRDF, AKBA, CVAC, and ELVN Headlines

Recent News About These Companies

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Should You Sell?

June 13 at 1:03 PM | marketbeat.com

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

June 13 at 9:30 AM | prnewswire.com

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 13 at 6:10 AM | prnewswire.com

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

June 13 at 6:02 AM | prnewswire.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares

June 12 at 9:12 AM | insidertrades.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 6,667 Shares of Stock

June 11 at 8:48 PM | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

June 11 at 3:28 AM | marketbeat.com

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.1% - Time to Buy?

June 10 at 4:08 PM | marketbeat.com

Bank of America Corp DE Sells 14,504 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

June 9, 2025 | marketbeat.com

Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4% on Insider Selling

June 8, 2025 | americanbankingnews.com

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4% on Insider Selling

June 6, 2025 | marketbeat.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 7,500 Shares

June 6, 2025 | insidertrades.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 7,500 Shares of Stock

June 5, 2025 | marketbeat.com

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 7,500 Shares of Stock

June 5, 2025 | marketbeat.com

Millennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

June 5, 2025 | marketbeat.com

Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

June 3, 2025 | marketbeat.com

What is Lifesci Capital's Forecast for ELVN FY2025 Earnings?

June 2, 2025 | marketbeat.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares

May 31, 2025 | marketbeat.com

Brokers Set Expectations for ELVN Q2 Earnings

May 31, 2025 | marketbeat.com

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 6.2% - Should You Buy?

May 30, 2025 | marketbeat.com

Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

May 30, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF, AKBA, CVAC, and ELVN Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.54 -0.12 (-3.15%)

As of 02:43 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Cardiff Oncology NASDAQ:CRDF

$3.72 -0.07 (-1.72%)

As of 02:44 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CureVac NASDAQ:CVAC

$5.54 -0.07 (-1.16%)

As of 02:43 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Enliven Therapeutics NASDAQ:ELVN

$22.14 +2.49 (+12.64%)

As of 02:44 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time